Women with PBC may be at high risk of disease flares after childbirth
Women with primary biliary cholangitis (PBC) may be at increased risk of having disease flares in the months following childbirth, according to a small…
Cholangitis
Liver Foundation honors family who turned diagnosis into giving
A family whose experience with biliary atresia led to an effort to help others navigate the challenges of pediatric liver disease is among those being…
Aramchol shows promise as PSC treatment, mouse study finds
Aramchol, a small molecule in the Galmed Pharmaceuticals pipeline, prevented and reversed inflammation and scarring (fibrosis) of the bile ducts in mouse models of…
ALF unveils network to connect living donors with strangers in need
The American Liver Foundation (ALF) is launching a first-of-its kind national database, called the ALF Living Donor Network, to connect people willing to…
Know your risks – and options – this National Liver Awareness Month
October is National Liver Awareness Month and Liver Cancer Awareness Month, and advocacy organizations across the U.S., including the American Liver Foundation (ALF), are…
PBC worst for life quality among autoimmune liver diseases: Study
Adults with autoimmune liver disease experience lower quality of life, especially those with primary biliary cholangitis (PBC), who report more fatigue, sleepiness, and pain…
Phase 2 trial of volixibat for PSC-related itching now fully enrolled
Enrollment is complete in the Phase 2b VISTAS clinical trial, which is testing the experimental oral treatment volixibat in people with itching due to…
PBC treatment Ocaliva leaves U.S. market amid safety concerns
Intercept Pharmaceuticals has voluntarily withdrawn Ocaliva (obeticholic acid), an oral therapy used to treat certain adults with primary biliary cholangitis (PBC), from…
Groups unite to fight liver disease during PBC Awareness Month
Members of the primary biliary cholangitis (PBC) community have come together in September as part of PBC Awareness Month to build support and share…
New trial data show saroglitazar works to ease liver damage in PBC
One year of treatment with saroglitazar, Zydus Therapeutics’ experimental oral candidate, outperformed a placebo at normalizing markers of liver injury in people with…
Recent Posts
- Livmarli eases Alagille teen’s itch following liver transplant issues
- US enrollment starts for hepatitis B gene therapy clinical trial
- Women with PBC may be at high risk of disease flares after childbirth
- Agrimonolide shows benefits in cholestasis mouse model
- The health risks of soda, including liver damage, are increasingly clear